source
- Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancerThe DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
- Eli Lilly to invest $4.5 billion in new manufacturing facilities across IndianaEli Lilly announced a $4.5 billion allocation for new manufacturing projects in Indiana. The company said the funds will be used to build and upgrade production sites across the state, expanding it…